Sources, scope and structure
How to read the Product Atlas
A public method for separating a useful product identity map from regulatory claims, clinical guidance, and marketing copy.
Research edition · 2026.09.06.1
Inside a product monograph
The new monographs add formulation, mechanism, indications, application considerations, contraindications, adverse effects, duration and comparisons. Every clinical paragraph links to its supporting source. The original identity dataset and its versioned downloads remain unchanged.
Germany, the United Kingdom, the United States and Australia have equal editorial priority and separate panels in every monograph. A regional brand relationship does not establish identical labels, formulations or approvals. A missing document means status is unverified in this edition, rather than evidence of non-approval.
Local regulatory records and official product information establish labeled uses. Scientific publications add clinical or mechanistic context; they cannot create an approved indication. Historical labels are dated and identified, and newer indication supplements are linked where found.
Study notes separate design, population, outcome, follow-up, interpretation and limitations. Abstract access is labeled explicitly. Source access and available funding disclosures are identified alongside each study. These selected papers are not a systematic review, and selection is not an endorsement or a ranking.
Monographs, study interpretations, comparisons and clinical topics each have a permanent URL, with section anchors for precise citations. Readers can move from a concise interpretation to the original source document.
A source check date records when a document was consulted; it does not certify that the document is the latest label in every market. The 3D illustrations are original conceptual material studies, not manufacturer packaging, authenticity references or injection diagrams.
1 · Scope
Scope of the original identity dataset
The original identity dataset helps readers distinguish a product family from a named variant, find the recorded manufacturer, understand the operational category used by Aesthetic Pass, and inspect the evidence status attached to that record.
It does not recommend a product, compare clinical performance, provide dosing or injection technique, confirm authenticity, or establish that a product is approved or available in a reader's country. Qualified professionals must use the locally current label, instructions for use, and regulatory record.
What is the recorded identity, who is the recorded maker, and what evidence layer is present?
Which product should be used, how it should be used, or whether it is suitable for a person.
2 · Record model
Three layers prevent false confidence
Breadth layer
A dated copy of the non-sensitive identity fields used by the mobile catalogue: product name, manufacturer, operational category, and any recorded active ingredient. This makes all 492 identities discoverable while retaining their catalogue-source context.
Evidence layer
A curated family profile adds aliases, material class, source scope, checked dates, and related product monographs.
Source context
A jurisdiction matrix and claim ledger connect individual statements to their source documents, limitations and evidence type.
3 · Sources
Primary evidence is claim-specific
A source is linked only to the field or statement it supports. A manufacturer page can establish brand identity; it cannot, by itself, establish regulatory status in every country. The public JSON exposes the same source IDs used by each jurisdiction finding and claim.
| Priority | Source type | Used for | Not assumed |
|---|---|---|---|
| 1 | Regulator database or decision | Jurisdiction-specific status and record identity | Status in another jurisdiction |
| 2 | Approved label or instructions for use | Exact presentation, composition, and labelled context | Interchangeability with other variants |
| 3 | Official manufacturer material | Brand, family, maker, and source-market context | Independent efficacy or superiority |
| 4 | Operational catalogue snapshot | Discovery and review-queue coverage | Approval, authenticity, safety, or current availability |
Retailer pages, distributor listings, search snippets, social posts, and AI-generated text are not accepted as final evidence for regulatory or clinical claims.
4 · Jurisdiction
No global approval language
Product names, legal classifications, authorised uses, presentations, labels, and availability can differ between countries. Every source carries a jurisdiction or source-market scope. Wording such as “approved,” “authorised,” or “indicated” is eligible only when it is tied to a current, product-specific source for the named jurisdiction.
5 · Reference URLs and editions
Cite the page, product and source.
The clinical reference and the original identity dataset have separate versions. Use a monograph or study URL for its current content, a section anchor for a particular statement, and a versioned dataset URL when citing the catalogue snapshot.
- 1
Exact presentation
Family, variant, manufacturer, formulation and regional name stay attached to the source.
- 2
Source documents
Each clinical paragraph points to the supporting label, regulator record or scientific publication.
- 3
Jurisdiction
Country-specific indications and status refer to that country's product information.
- 4
Study context
Design, population, endpoint, follow-up and limitations accompany the findings.
- 5
Permanent references
Individual pages and section anchors make products, studies and comparisons directly linkable.
- 6
Version history
Dated identity releases retain their original files and checksums; current references can incorporate new sources.
6 · Coverage
Current snapshot, including the gaps
- Catalogue identities
- 492
- Manufacturers
- 91
- Operational categories
- 9
- Source-linked profiles
- 11
- Visible primary-source gaps
- 0
The current evidence layer contains 21 source-market records and 23 bounded claims. Family-level sources provide context for related identities; exact variants require their own product information.
| Operational category | Identities |
|---|---|
| Dermal fillers | 157 |
| Mesotherapy products | 133 |
| Skin boosters / biostimulators | 124 |
| Chemical peels | 48 |
| Fat-dissolving injectables | 20 |
| Neuromodulators | 3 |
| Energy-based devices | 3 |
| Microneedling devices | 2 |
| PRP / PRF systems | 2 |
Counts describe the Aesthetic Pass operational catalogue snapshot on 14 August 2026; they do not estimate the size of any national or global market.
7 · Corrections
Make errors easy to challenge
Correction requests should include the atlas URL, exact disputed field, jurisdiction, and a current primary source. We record material revisions through a new checked date and dataset version. Use the structured Atlas contribution form; never send patient information.
Material public changes are recorded in the release history and diff contract.
This method operates alongside the broader Aesthetic Pass editorial and corrections policy.